The 14th International Symposium on Anti-Angiogenic Agents took place in La Jolla, California, from February 2-4, 2012.
Angiongenesis is an essential process in the growth of neoplasms and progression to metastasis.
This annual state-of-the-art symposium on anti-angiogenic agents provides a forum for research and clinical investigators to review the current scientific understanding of vascular biology and angiogenesis. Many new and unpublished data were presented.
Here is a round-up.
Recent FDA approval of anti-angiogenic drugs has given the industry a boost, including:
-- Sunitunib for neuroendocrine tumors;
-- Vandetanib for medullary thyroid carcinoma;
-- Axitinib for renal cell carcinoma;
-- Avastin (bevacizumab) in advanced metastatic colorectral cancer;
-- Avastin as maintenance therapy in ovarian cancer;
-- VEGFtrap (aflibercept) as second line therapy for colorectal cancer.
Some early-phase trial information included:
-- Eye opening Phase I data showing evidence of clinical activity from PF03446962, an anti-ALK-1 monoclonal antibody from Pfizer, a compound that inhibits angiogenesis in a way complementary to anti-VEGF therapies.
-- Early, promising Phase 1b trial results with Genentech's MEGF0444A, a humanized monoclonal antibody against the epidermal growth factor-like domain 7, which is enriched in tumor vascular matrix after Avastin (bevacizumab) treatment.
Source: OncLive
The information provided on CancerTreatment.net is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational purposes and does not constitute the practice of medicine. We encourage all visitors to see a licensed physician or nutritionist if they have any concerns regarding health issues related to diet, personal image and any other topics discussed on this site. Neither the owners or employees of CancerTreatment.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.
